[Consensus on linezolid in the treatment of tuberculosis(2022 update)].

Linezolid is the core drug for the treatment of multidrug-resistant tuberculosis. In 2018, Chinese Society for Tuberculosis, Chinese Medical Association(CSTB) issued a "consensus on linezolid in the treatment of tuberculosis". With the wider use of it in clinic, the improved understanding and the progress in research, CSTB organized experts to update this consensus and formed "consensus on linezolid in the treatment of tuberculosis(2022 update)", with a view to play a guiding role for clinicians. The consensus included the molecular structure and mechanism of action, pharmacodynamics, pharmacokinetics, clinical application, indications, contraindications and relative contraindications, dosage, usage and formulation of chemotherapy regimen, adverse reactions and clinical application. In this edition, we updated the drug resistance mechanism of linezolid, and the medical evidence was rated and recommended according to the grading of recommendations assessment, development and evaluation (GRADE) method.